Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Leukemia, Promyelocytic, Acute 1Breast Neoplasms 1

Interventions

pembrolizumab 1285Specimen Handling 928Carboplatin 837Magnetic Resonance Spectroscopy 834Cyclophosphamide 808Cisplatin 736Nivolumab 681Paclitaxel 635Radiotherapy 618Gemcitabine 580Biopsy 560Bevacizumab 486Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 363Fluorouracil 358atezolizumab 353durvalumab 340Rituximab 336Drug Therapy 334Radiosurgery 321Doxorubicin 320Blood Specimen Collection 317Standard of Care 311Pemetrexed 308Ipilimumab 303Radiation 289

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
arsenous acid × 1 year × Clear all
NCT01409161 2026-05-20

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
151 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06678048 2025-06-06

Arsenous Acid for Refractory Triple-Negative Breast Cancer

Sun Yat-sen University

Phase 2 Recruiting
12 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡